Radiation Dose for Non-Surgical Treatment of Rectal Cancer
For patients pursuing organ preservation without surgery, the standard radiation dose is 45-50.4 Gy delivered in 25-28 fractions (1.8-2.0 Gy per fraction) with concurrent 5-fluorouracil-based chemotherapy. 1, 2, 3
Standard Dosing Regimen
The most widely endorsed approach across multiple international guidelines consists of:
- Pelvic radiation: 45.0-50.4 Gy in 25-28 fractions
- Fraction size: 1.8-2.0 Gy per fraction
- Treatment duration: 5-6 weeks
- Concurrent chemotherapy: 5-FU-based regimen throughout radiation 1, 2, 3
Boost Considerations
After delivering the initial 45 Gy, an additional boost may be considered:
- For organ preservation attempts: Additional 5.4 Gy in 3 fractions (total 50.4 Gy) 1, 2
- For unresectable tumors: Doses may be escalated to 54-56 Gy if technically feasible and surrounding normal tissues tolerate it 1, 2
Concurrent Chemotherapy Options
The radiation must be combined with concurrent 5-FU-based chemotherapy. The preferred regimens are:
Primary Options:
- Continuous infusion 5-FU: 225 mg/m² over 24 hours, 7 days/week during radiation 2
- Capecitabine: 825 mg/m² twice daily, 5 days per week during radiation 1, 2
Alternative Option:
- Bolus 5-FU/leucovorin: 5-FU 400 mg/m² IV bolus + leucovorin 20 mg/m² IV bolus for 4 days during weeks 1 and 5 of radiation 2
Continuous infusion 5-FU is likely superior to bolus administration based on comparative data, though both are acceptable 3, 4.
Treatment Field Requirements
The radiation field must include 1, 2:
- Tumor or tumor bed with 2-5 cm margin
- Presacral lymph nodes
- Internal iliac lymph nodes
- Obturator lymph nodes
- External iliac lymph nodes (for T4 tumors invading anterior structures)
Critical Dose Constraints
Small bowel dose must be limited to ≤45 Gy to minimize toxicity 1, 2, 5. Use positioning techniques and modern radiation delivery (3D-CRT, VMAT, or IMRT) to minimize small bowel exposure 1.
Alternative Short-Course Approach
For patients who cannot tolerate long-course chemoradiotherapy (elderly, significant comorbidities):
- Short-course radiation: 25 Gy in 5 fractions over 1 week
- Followed by: Delayed surgery at 6-8 weeks OR observation for organ preservation 3, 6
However, this short-course approach with delayed surgery is primarily for patients who will ultimately undergo surgery, not for definitive organ preservation strategies 3, 6.
Organ Preservation Strategy
For patients specifically pursuing a "watch-and-wait" organ preservation approach:
- Deliver full-dose chemoradiotherapy (50.4 Gy with concurrent 5-FU-based chemotherapy)
- Consider consolidation chemotherapy after chemoradiotherapy 1
- Reassess at 6-8 weeks post-treatment
- If clinical complete response (cCR) achieved, close surveillance without immediate surgery 3, 6
The most recent CSCO guidelines (2025) specifically recommend prioritizing the model of chemoradiotherapy followed by consolidation chemotherapy when non-surgical treatment is the goal 1.
Important Caveats
- Total treatment duration (including chemotherapy and radiotherapy) should not exceed 6 months 1
- Patients must have good performance status and be carefully selected for organ preservation approaches
- Close surveillance is mandatory following organ preservation attempts, as salvage surgery may be needed for incomplete response or recurrence 3, 6
- The addition of oxaliplatin or other agents to standard 5-FU/radiation remains investigational and has not shown consistent benefit in randomized trials 3, 4